Exelixis Inc (EXEL) - News Archive

Exelixis, Inc. (Nasdaq: EXEL) has announced the results of a subgroup analysis from the CABINET phase 3 pivotal trial evaluating the efficacy of CABOMETYX (cabozantinib) against a placebo in patients with advanced neuro...

In a significant advancement in cancer treatment, Exelixis, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX (cabozantinib) for patients aged 12 years and older with previously...

ALAMEDA, Calif. Exelixis, Inc. (Nasdaq: EXEL) recently made a significant impact in the oncology community with new findings from the CheckMate -9ER trial, evaluating the efficacy of CABOMETYX (cabozantinib) in combinat...

In an exciting development in the treatment of advanced renal cell carcinoma (RCC), Exelixis, Inc. (Nasdaq: EXEL) has announced the compelling five-year follow-up results from the phase 3 CheckMate -9ER trial. Presented...

The biotechnology firm Exelixis, Inc. (Nasdaq: EXEL), based in Alameda, California, has made significant strides in both clinical and legal domains. Recently, the company revealed promising results from a subgroup analy...

Exelixis, Inc. (Nasdaq: EXEL), based in Alameda, California, has recently provided significant updates regarding its lead compound, cabozantinib (CABOMETYX), alongside strategic developments within its patent portfolio...

In a series of significant updates, Exelixis, Inc. has made waves in the biopharmaceutical landscape through a combination of legal victories, clinical collaborations, and promising clinical trial results. As the compan...

In a significant development for the pharmaceutical industry, Exelixis, Inc. has achieved a favorable ruling in its ongoing patent litigation against MSN Laboratories Private Limited. The U.S. District Court for the Dis...

In a noteworthy collaboration, Exelixis, Inc. a prominent biotechnology firm, and Merck, an established giant in the pharmaceutical industry, have embarked on a clinical development partnership aimed at enhancing cancer...

In a groundbreaking development for oncological pharmacotherapy, Exelixis, Inc. unveils compelling final results from its Phase 3 pivotal CABINET study, evaluating the efficacy of cabozantinib (trade name CABOMETYX) aga...

In a significant advancement in cancer therapy, Exelixis, Inc. (NASDAQ: EXEL) has announced the commencement of the dose-escalation stage of a Phase 1 clinical trial for XB010, an innovative antibody-drug conjugate (ADC...

By MADISON, Wisc. Invenra, a leading biotherapeutics company, is celebrating a significant milestone with its collaboration partner, Exelixis, Inc. (NASDAQ: EXEL). Exelixis recently announced the initiation of the dose-...

Cabozantinib Receives FDA Nod for Advanced Neuroendocrine Tumors: What This Means for Exelixis Future Exelixis, Inc. has been at the forefront of oncological innovations, and their recent breakthrough is no less impress...

In an announcement today, biotechnology company Exelixis, Inc. revealed that it has successfully settled a patent dispute with pharmaceutical firm Cipla Ltd. and its subsidiary Cipla USA, Inc. This settlement comes as a...